{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T20:45:32Z","timestamp":1775853932593,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00277-019-03889-3","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T10:03:25Z","timestamp":1577095405000},"page":"283-291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study"],"prefix":"10.1007","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9320-9334","authenticated-orcid":false,"given":"Luigi","family":"Rigacci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjola","family":"Dona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Gotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Bonfichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Stelitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Nassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Kovalchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Gioia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"3889_CR1","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin\u2019s disease: International Prognostic Factors Project on advanced Hodgkin\u2019s disease. N Engl J Med 339:1506\u20131514","journal-title":"N Engl J Med"},{"key":"3889_CR2","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","volume":"27","author":"T Terasawa","year":"2009","unstructured":"Terasawa T, Lau J, Bardet S et al (2009) Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin\u2019s lymphoma and diffuse large B-cell lymphoma: A systemic review. J Clin Oncol 27:1906\u20131914","journal-title":"J Clin Oncol"},{"key":"3889_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","volume":"107","author":"M Hutchings","year":"2006","unstructured":"Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52\u201359","journal-title":"Blood"},{"key":"3889_CR4","first-page":"475","volume":"91","author":"A Gallamini","year":"2006","unstructured":"Gallamini A, Rigacci L, Merli F et al (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin\u2019s disease. Haematologica 91:475\u2013481","journal-title":"Haematologica"},{"key":"3889_CR5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/annonc\/mdl122","volume":"17","author":"PL Zinzani","year":"2006","unstructured":"Zinzani PL, Tani M, Fanti S et al (2006) Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin\u2019s disease patients. Ann Oncol 17:1296\u20131300","journal-title":"Ann Oncol"},{"key":"3889_CR6","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","volume":"25","author":"A Gallamini","year":"2007","unstructured":"Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746\u20133752","journal-title":"J Clin Oncol"},{"key":"3889_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00259-011-1916-8","volume":"39","author":"PL Zinzani","year":"2012","unstructured":"Zinzani PL, Rigacci L, Stefoni V et al (2012) Early interim 18F-FDG PET in Hodgkin\u2019s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging 39:4\u201312","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3889_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1100340","volume":"365","author":"S Viviani","year":"2011","unstructured":"Viviani S, Zinzani PL, Rambaldi A et al (2011) ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned. N Engl J Med 365:203\u2013212","journal-title":"N Engl J Med"},{"key":"3889_CR9","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdu189","volume":"25","author":"N Mounier","year":"2014","unstructured":"Mounier N, Brice P, Bologna S et al (2014) ABVD (8 cycles) versus BEACOPP (4 escalated cycles > 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 25:1622\u20131628","journal-title":"Ann Oncol"},{"issue":"10","key":"3889_CR10","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3324\/haematol.2017.167478","volume":"102","author":"DA Eichenauer","year":"2017","unstructured":"Eichenauer DA, Becker I, Monsef I et al (2017) Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. Haematologica 102(10):1748\u20131757. https:\/\/doi.org\/10.3324\/haematol.2017.167478","journal-title":"Haematologica"},{"issue":"2","key":"3889_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","volume":"31","author":"K Behringer","year":"2013","unstructured":"Behringer K, Mueller H, Goergen H et al (2013) (2012) Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol 31(2):231\u2013239. https:\/\/doi.org\/10.1200\/JCO.2012.44.3721","journal-title":"J Clin Oncol"},{"issue":"10114","key":"3889_CR12","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","volume":"390","author":"P Borchmann","year":"2018","unstructured":"Borchmann P, Goergen H, Kobe C et al (2018) PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 390(10114):2790\u20132802. https:\/\/doi.org\/10.1016\/S0140-6736(17)32134-7","journal-title":"Lancet"},{"key":"3889_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/j.1365-2141.2010.08485.x","volume":"152","author":"A Gallamini","year":"2011","unstructured":"Gallamini A, Patti C, Viviani S et al (2011) Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 152:551\u2013560","journal-title":"Br J Haematol"},{"key":"3889_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ajh.22187","volume":"87","author":"EJ Dann","year":"2012","unstructured":"Dann EJ, Blumenfeld Z, Bar-Shalom R et al (2012) A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved. Am J Hematol 87:32\u201336","journal-title":"Am J Hematol"},{"issue":"17","key":"3889_CR15","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 372(17):1598\u20131607","journal-title":"N Engl J Med"},{"issue":"16","key":"3889_CR16","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M et al (2017) Early positron emission tomography response-adapted treatment in stage I and II HodgkinLymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol 35(16):1786\u20131794","journal-title":"J Clin Oncol"},{"issue":"4","key":"3889_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","volume":"18","author":"P Borchmann","year":"2017","unstructured":"Borchmann P, Haverkamp H, Lohri A et al (2017) Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin\u2019s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol 18(4):454\u2013463","journal-title":"Lancet Oncol"},{"issue":"5","key":"3889_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","volume":"36","author":"A Gallamini","year":"2018","unstructured":"Gallamini A, Tarella C, Viviani S et al (2018) Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial. J Clin Oncol 36(5):454\u2013462","journal-title":"J Clin Oncol"},{"issue":"12","key":"3889_CR19","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","volume":"34","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Broccoli A, Gioia DM et al (2016) Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol 34(12):1376\u20131385","journal-title":"J Clin Oncol"},{"issue":"25","key":"3889_CR20","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 374(25):2419\u20132429","journal-title":"N Engl J Med"},{"issue":"17","key":"3889_CR21","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","volume":"34","author":"OW Press","year":"2016","unstructured":"Press OW, Li H, Schoder H et al (2016) US Intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomognraphy imaging: Southwest Oncology Group S0816. J Clin Oncol 34(17):2020\u20132027","journal-title":"J Clin Oncol"},{"issue":"5","key":"3889_CR22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid ME, Stroobants S, Hoekstra OS et al (2007) Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571\u2013578","journal-title":"J Clin Oncol"},{"issue":"6","key":"3889_CR23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3324\/haematol.2013.103218","volume":"99","author":"A Gallamini","year":"2014","unstructured":"Gallamini A, Barrington SF, Biggi A et al (2014) The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. Haematologica 99(6):1107\u20131113","journal-title":"Haematologica"},{"key":"3889_CR24","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(13)70341-3","volume":"14","author":"N Skoetz","year":"2013","unstructured":"Skoetz N, Trelle S, Rancea M et al (2013) Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin\u2019s lymphoma: a systematic review and network meta-analysis. Lancet Oncol 14:943\u2013952","journal-title":"Lancet Oncol"},{"issue":"4","key":"3889_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/bjh.14292","volume":"175","author":"C Mesguich","year":"2016","unstructured":"Mesguich C, Cazeau AL, Bouabdallah K et al (2016) Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol 175(4):652\u2013660","journal-title":"Br J Haematol"},{"issue":"10","key":"3889_CR26","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1182\/blood-2008-06-155820","volume":"112","author":"C Kobe","year":"2008","unstructured":"Kobe C, Dietlein M, Franklin J et al (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112(10):3989\u20133994","journal-title":"Blood"},{"issue":"4","key":"3889_CR27","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1093\/annonc\/mdq549","volume":"22","author":"JA Barnes","year":"2011","unstructured":"Barnes JA, LaCasce AS, Zukotynski K et al (2011) End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin\u2019s lymphoma. Ann Oncol 22(4):910\u2013915","journal-title":"Ann Oncol"},{"issue":"5","key":"3889_CR28","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.hoc.2007.06.011","volume":"21","author":"BD Cheson","year":"2007","unstructured":"Cheson BD (2007) The International Harmonization Project for response criteria in lymphoma clinical trials. Hematol Oncol Clin North Am Rev 21(5):841\u2013854","journal-title":"Hematol Oncol Clin North Am Rev"},{"issue":"12","key":"3889_CR29","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","volume":"127","author":"SF Barrington","year":"2016","unstructured":"Barrington SF, Kirkwood AA, Franceschetto A et al (2016) PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study. Blood 127(12):1531\u20131538","journal-title":"Blood"},{"issue":"14","key":"3889_CR30","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","volume":"36","author":"P Armand","year":"2018","unstructured":"Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol 36(14):1428\u20131439","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03889-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03889-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03889-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:12:20Z","timestamp":1608595940000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03889-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["3889"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03889-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]},"assertion":[{"value":"15 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Patients signed informed consent, after internal institutional review board approval, to participate at the clinical study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}